Currently, the second-generation anti-angiogenic agent Faricimab, which simultaneously targets VEGF and ANGPT2, has completed phase III clinical trials for AMD, demonstrating significant efficacy (ClinicalTrials.gov: NCT03823287, NCT03823300) (Khanani et al., 2024, p. 2). Here, ANGPT2 is linked to age-related macular degeneration.